Trial Profile

A trial to investigate the efficacy, safety and tolerability of an intravenous infusion of HZN-001 compared with placebo in treating male and female Japanese participants at least 18 years of age with chronic (inactive) thyroid eye disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 May 2023 New trial record
01 May 2023 According to a Horizon Therapeutics plc media release, this trial will build on a separate Phase 3 clinical trial (OPTIC-J). The trial was designed in consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
01 May 2023 According to a Horizon Therapeutics plc media release, first patient has been enrolled in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com